Aaron Rosenberg, M.D., M.S.

Aaron Seth Rosenberg, M.D., M.S.





Internal Medicine


  • Associate Professor (Clin-X), Department of Internal Medicine, Division of Hematology and Oncology


To see if Aaron Seth Rosenberg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Clinic Fax: 916-706-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Rosenberg's clinical interests include the diagnosis and care of multiple myeloma, and lymphoid malignancies, as well as the management of thrombosis. He is a member of the adult hematopoietic stem cell transplant team.

Research/Academic Interests

Dr. Rosenberg focuses on outcomes research related to hematologic malignancies and thrombosis, as well as developing clinical trials for patients with hematologic malignancies.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center


M.D., Mount Sinai School of Medicine, New York City, NY 2006

M.S., Sackler School of Biomedical Research, Boston MA 2014

B.A., Wesleyan University, Middletown CT 2001

Internship: Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009


Internal Medicine, Temple University Hospital, Philadelphia PA 2006-2009

Internal Medicine, UC San Francisco, San Francisco CA 2013-2015


Hematology/Oncology, Tufts Medical Center, Boston MA 2010-2013

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Hematology,

American Board of Internal Medicine, Medical Oncology,

Professional Memberships

American Medical Association

American Society of Clinical Oncology

American Society of Hematology

Select Recent Publications


Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A. Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Rev. 2020 Feb 21;100672. doi:10.1016/j.blre.2020.100672.

Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clinical Lymphoma, Myeloma & Leukemia. 2020;20(7):453-458. doi:10.1016/j.clml.2020.02.006.

Abrahão R, Ribeiro RC, Lichtensztajn DY, Rosenberg AS, Keegan THM. Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A populationbased study. Pediatric Blood & Cancer. 2019 Apr;66(4):e27559. doi:10.1002/pbc.27559. Epub 2018 Dec 4.

Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. J Natl Cancer Inst. 2018 Jan;111(1):78-85. Published online 2018 Jun 11. doi:10.1093/jnci/djy073.

Gupta S, Abouzaid A, Liebert R, Parikh K, Ung B, Rosenberg AS. Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. 2018 Mar;18(3):210-218. doi:10.1016/j.clml.2018.01.006. Epub 2018 Jan 31.

Pon TK, Mahajan A, Rosenberg AS, Amin A, Shah D, Jenkins I, Gupta V, Hofmann H, Bejjani A, White R. Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2018 May;45(4):536-542. doi:10.1007/s11239-018-1646-x.

Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM. Decreased early mortality associated with treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018 Feb 15;124(9):1938-1945. doi:10.1002/cncr.31296.

Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. JAMA Oncol. 2017 Nov;3(11):1554-1557. doi:10.1001/jamaoncol.2017.0465.

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017 Jul;178(1): 72-80. doi:10.1111/bjh.14638. Epub 2017 May 25.

Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017 Jul;178(2):319-326. doi:10.1111/bjh.14655. Epub 2017 Apr 3.